MedTrace Logo

The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus

NCT01608724 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2165

Last updated 2016-02-02

Study results available
· View outcomes & findings →

Summary

The efficacy and safety study of saxagliptin 5mg, once daily for 24 weeks in patients with type 2 diabetes mellitus.

Conditions

  • Diabetes Mellitus, Non-Insulin-Dependent

Interventions

DRUG

Saxagliptin

oral, 5 mg once a day (Q.D.)

Sponsors & Collaborators

Principal Investigators

  • Simon Fisher · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01608724 on ClinicalTrials.gov